The Effects of Multiple Infusion Line Extensions on Occlusion Alarm Function of an Infusion Pump

2009 ◽  
Vol 108 (2) ◽  
pp. 518-520 ◽  
Author(s):  
Diana Deckert ◽  
Christian Buerkle ◽  
Andreas Neurauter ◽  
Peter Hamm ◽  
Karl H. Lindner ◽  
...  
Neurosurgery ◽  
1986 ◽  
Vol 19 (5) ◽  
pp. 779-783 ◽  
Author(s):  
P. Kapp John ◽  
A. Sanford Robert

Abstract The records of 24 patients with malignant gliomas treated with carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) are reviewed for risk factors that might suggest the development of a permanent neurological deficit after infusion. Permanent neurological deficits were seen with doses of cisplatin as low as 69 mg/m2, although doses as high as 100 mg/m2 were tolerated by other patients. All 3 patients who developed permanent neurological deficits received fixed doses of cisplatin of 150 mg and supplied only 2 major intracranial branches from the infused carotid artery. In none of these patients was a filter used in the infusion line. Other risk factors identified in 2 of the 3 patients were diffuse neoplasm involving the region of the internal capsule and the use of an infusion pump rather than a pulsatile bolus infusion technique. The development of a permanent neurological deficit appeared unrelated to the dose of BCNU within the range utilized, and preinfusion administration of corticosteroids did not prevent neurological deficit. These possible risk factors should be considered in the future development of protocols for arterial infusion therapy of malignant gliomas.


2020 ◽  
Vol 59 (04) ◽  
pp. 323-331
Author(s):  
Christian Kühnel ◽  
Thomas Winkens ◽  
Tobias Niksch ◽  
Julia Greiser ◽  
Steffen Schrott ◽  
...  

Abstract Aim Intravenous radionuclide therapies are gaining importance. With the increased frequency of these therapies, safe application procedures in combination with effective radiation protection are needed. We present a shielded system which can be universally used for the application of liquid radiopharmaceuticals. Materials and methods The application system consists of a cuboidal box made of lead with stainless steel coating, an inner layer of polymethyl methacrylate (PMMA), a disposable line/bottle system, and a medical infusion pump. No proprietary disposable parts are used. The system was tested and validated ex-vivo, and evaluated for Lu-177 peptide receptor radionuclide and for radioligand therapies (PRRT, RLT). Results Construction of the application system was performed in accordance with the physical characteristics of the used isotopes. 10 validation procedures with 1 GBq Tc-99m-pertechnetate confirmed functionality. 38 PRRT and 13 RLT procedures were performed successfully and completely. At least 98 % of the prescribed activities were infused. No leakage of radioactivity occurred. Dose rate measurements showed that the radiation in the box is shielded completely, and that exposure arises only from the infusion line outside the box and from the patient. Conclusion The presented application system for intravenous radionuclide therapies is feasible, safe, and cost-efficient. It has been shown that Lu-177-PRRT and -RLT can be performed without complications while ensuring nearly complete infusion of the prescribed radiopharmaceutical dose. Radiation exposure of the applying physician and other staff is low. The construction of the shielding box ensures complete shielding of all radionuclides currently used for radiomolecular therapies.


Author(s):  
Liying Mu ◽  
Milind Dawande ◽  
Srinagesh Gavirneni ◽  
Chelliah Srishkandarajah
Keyword(s):  

Author(s):  
Anthony Ryan Hatch ◽  
Julia T. Gordon ◽  
Sonya R. Sternlieb

The new artificial pancreas system includes a body-attached blood glucose sensor that tracks glucose levels, a worn insulin infusion pump that communicates with the sensor, and features new software that integrates the two systems. The artificial pancreas is purportedly revolutionary because of its closed-loop design, which means that the machine can give insulin without direct patient intervention. It can read a blood sugar and administer insulin based on an algorithm. But, the hardware for the corporate artificial pancreas is expensive and its software code is closed-access. Yet, well-educated, tech-savvy diabetics have been fashioning their own fully automated do-it-yourself (DIY) artificial pancreases for years, relying on small-scale manufacturing, open-source software, and inventive repurposing of corporate hardware. In this chapter, we trace the corporate and DIY artificial pancreases as they grapple with issues of design and accessibility in a content where not everyone can become a diabetic cyborg. The corporate artificial pancreas offers the cyborg low levels of agency and no ownership and control over his or her own data; it also requires access to health insurance in order to procure and use the technology. The DIY artificial pancreas offers patients a more robust of agency but also requires high levels of intellectual capital to hack the devices and make the system work safely. We argue that efforts to increase agency, radically democratize biotechnology, and expand information ownership in the DIY movement are characterized by ideologies and social inequalities that also define corporate pathways.


Author(s):  
Peter Hoogevest ◽  
Harry Tiemessen ◽  
Josbert M. Metselaar ◽  
Simon Drescher ◽  
Alfred Fahr

1999 ◽  
Vol 10 (6) ◽  
pp. 727-729 ◽  
Author(s):  
D. Zahnd ◽  
S. Aebi ◽  
S. Rusterholz ◽  
M.F. Fey ◽  
M.M. Borner

1986 ◽  
Vol 144 (2) ◽  
pp. 74-77 ◽  
Author(s):  
Frederick O. Stephens ◽  
Paul Crea ◽  
Phillip J. Walker
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document